Alnylam Pharmaceuticals

ALNY | NASDAQ | 1 Obserwujący

$291.86

+2.30%

$6.55

Obserwuj

Overview Metrics Financials

Fair Price

$188.08

Overvalued by 92.5%

Aby wyświetlić sprawiedliwą cenę akcji, musisz być członkiem Bulios Black.

Profile

Alnylam Pharmaceuticals, Inc. is an American biotechnology company headquartered in Cambridge, Massachusetts. It focuses on the development of RNA-based therapeutics for the treatment of genetic diseases. The company specializes in RNA interference (RNAi) technology, which allows for the suppression of specific genes expression to treat genetic diseases at the gene level. Their research and development efforts target the treatment of various genetic diseases, including liver, kidney, muscle, and nervous system disorders. Alnylam Pharmaceuticals is known for its innovative approach to RNAi research and development of therapeutic agents for the treatment of rare diseases. The company collaborates with academic institutions, biotechnology firms, and pharmaceutical companies worldwide. Shares of Alnylam Pharmaceuticals, Inc. are publicly traded on the NASDAQ stock exchange.

Feed

There are no posts to show right now.

Menu StockBot

Tracker

Upgrade

Alnylam Pharmaceuticals

Fair Price

Profile

Feed

Zaloguj się do Bulios

Utwórz profil Bulios

Dlaczego Bulios?